Restructuring
2
2 restructurings since 2025. Latest: merger with MEDVIA.
FBM
Overview
Lifetime
1 annual account with figurespeak €1.4m (2025)
€1.4m
lowest -€503,079 (2025)
-€503,079
peak €782,076 (2025)
€782,076
€1.1m
peak 14 FTE (2025)
14 FTE
Board29 names since 2024all names
25 directorsAphea.Bio and 24 others
Documentsfilings and deeds
27-05-202665 days before the deadline
2025abbreviated format
Loss of €503,0796 directors appointed, 8 resignations 03-10Merger: FBM takes over FLANDERS.BIO 24-03Amendment of the articles 24-02Powers of attorney: Ann Van Gysel and Marc Ost 24-021 establishment registered
Key points
from the 2025 annual accountsPosition in the sector
-€503,079
Lower net result than 95% of companies in office administrative support. Sector median €20,953 · 2,830 companies.
Public support
€190,539 awarded in 2025
EU support: Horizon Europe.
Checked score
91
Excellent
Financially stronger than 27% of small companies in office administrative support (NACE 82)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 1,123 companies (NACE 82, small).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2025: < 0.1%lowest value
01-2026: < 0.1%● unchanged vs 12-2025lowest value
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026highest value
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Loss of €503,079 (financial year 2025)
Size: turnover €1.4m, 14 FTE, total assets €1.9m
lowers risk
Legal form: non-profit association
Sector: Office administrative, office support and other business support activities (NACE 82)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 82, small). It does better than 49% of them on solvency, 31% on liquidity and 1% on profitability.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 1,683 companies had the same profile as FBM has now. Each dot stands for 5 companies, two years later.
90.7%
were still trading
7.7%
stopped another way
1.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of FBM itself is lower: < 0.1% within 12 months. It rests on far more data about FBM than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,683 companies, not a prediction for FBM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €70,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity is ample, with a current ratio of 2.03, above the usual 1.5. Short-term debt is 41.6% and cash 9.8% of total assets. However, 59.2% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-05-2026, 65 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
65 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
Recent changes
6 directors appointed, 8 resignations
Resignations: Galapagos, Virovet, MoveUp, Montis Biosciences, QbD 'Group, Heran Partners and 2 others · Permanent representatives: Marieke Vermeersch, Erwin Blomsma, Ward Servaes, Gil Beyen, Bart Van Acker, Herman Verrelst and 4 others · Appointments: Allegro, Flen Health, Benno Therapeutics, Gynaia, Ad Hoc Clinical and Tom Aelbrecht (permanent representative) · General meeting of 27-05-2025 · Gazette deed
Merger: FBM takes over FLANDERS.BIO
Appointments: MONTIS BIOSCIENCES BV, APHEA.BIO NV, VIROVET NV, GALAPAGOS NV, VIB VZW, P.M.V. NV and 10 others · Permanent representatives: Gil Hendrik August BEYEN, Isabel Julia René VERCAUTEREN, Erwin BLOMSMA, Marieke Francine VERMEERSCH, Jérôme Laurent Nicole VAN BIERVLIET, Kenneth Maria WILS and 10 others · Resignations: FLANDERS.BIO (director) and MEDVIA (director) · General meeting of 18-02-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1016786167
Amendment of the articles
General meeting of 06-01-2025 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| FBM Ghent | €1.4m | -36.8% | 40.8% | 14 |
| Agricotrans Léglise | €2.4m | 5.7% | 1.5% | 8.8 |
| Bier Central Anspach Brussels | - | - | 38.1% | 14.6 |
| AG REAL ESTATE COPRODUCTION IN DEVELOPMENT 2 Brussels | - | - | -54.6% | 9.1 |
| ACCESS SOLUTIONS BELGIUM Machelen (Brab.) | - | - | 54.7% | 5.3 |
| AdaptX Kontich | €2.5m | 6.1% | 16.4% | 11.4 |
| ART BLANC Waterloo | - | - | 2.7% | 8.6 |
Grey: the largest companies of the sector (office administrative support (NACE 82)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as FBM: other business support services (NACE 82990). They are comparable in size and age: total assets between €694,000 and €3m, founded between 2022 and 2024.
Official details
Source: KBO- Status
- Active since 29-11-2024Normal situation
- Activity
- Other business support servicesNACE 82990and 5 others
- Joint committee
- 335Services and support for business and the self-employed · annual accounts 2025
- Establishment unit
- 2.370.455.3169000 Ghent, since 18-02-2025
- Financial year end
- 31 December
- Peppol
- Reachable since 05-03-2025
Annual accounts 2025
- €1.4m
- €503,079
- €782,076
- €1.9m
- Employeeson 31-12-2025
- 17
- Filing
- Filed on 27-05-2026, 65 days before the end of the filing period
Insights on FBM
FBM has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €782,076 and a net result of -€503,079.
Its solvency ranks better than 50% of 2,828 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
abbreviated format, filed on 27-05-2026, 65 days before the deadline€1.4m
-€498,556
-€390,316
-€394,839
40.8%
2.03
Money flows
turnover is 32.3% of income in 2025Balance sheet
balance sheet total €1.9m on 31-12-2025What the company ownsHow it is paid for
Position in the sector
40.8%
Higher than 50% of 2,828 companies in 2025.
2.03
Higher than 63% of 2,718 companies in 2025.
-26.2%
Lower than 95% of 2,776 companies in 2025.
FBM
Middle half of the sector
80% of the sector
Abbreviated accounts in office administrative support (NACE 82)
Net result: bottom quarter · Equity: middle half · Balance sheet total: middle half · Working capital: top quarter · Staff: top quarter
Staff
€111,234
Staff costs divided by the average number of full-time equivalents.
+17 people
people who joined
people who left
In 2025, 22 people joined and 5 left.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 |
|---|---|---|
| Balance sheet: assets | ||
20/58 |
1.9m | |
20 |
121,457 | |
21/28 |
179,058 | |
21 |
62,869 | |
22/27 |
116,189 | |
23 |
2,921 | |
24 |
113,268 | |
29/58 |
1.6m | |
40/41 |
467,549 | |
40 |
373,748 | |
41 |
93,801 | |
50/53 |
300,866 | |
54/58 |
187,124 | |
490/1 |
660,607 | |
| Balance sheet: equity and liabilities | ||
10/49 |
1.9m | |
10/15 |
782,076 | |
13 |
436,091 | |
14 |
345,985 | |
17/49 |
1.1m | |
17 |
49,429 | |
170/4 |
49,429 | |
42/48 |
797,303 | |
42 |
19,668 | |
44 |
575,645 | |
440/4 |
575,645 | |
45 |
186,997 | |
450/3 |
1,609 | |
454/9 |
185,388 | |
47/48 |
14,993 | |
492/3 |
287,853 | |
| Income statement | ||
70 |
1.4m | |
73 |
2.3m | |
76A |
2,278 | |
9900 |
1.2m | |
60/61 |
2.5m | |
62 |
1.6m | |
630 |
108,240 | |
640/8 |
3,180 | |
9901 |
-498,556 | |
75/76B |
10,181 | |
75 |
10,181 | |
65/66B |
12,470 | |
65 |
12,470 | |
9903 |
-500,845 | |
67/77 |
2,234 | |
9904 |
-503,079 | |
9905 |
-503,079 | |
| Appropriation of the result | ||
9906 |
-503,079 | |
791 |
849,064 | |
| Social balance sheet | ||
9087 |
14 | |
Hours worked1013 |
19,143 | |
| Document | ||
The notes to these accounts have 18 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 27-05-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 27-05-2026 | 2026-00122619 |
Subsidies and aid
Flemish government 2025, 4 entries, -€250 awarded, €524,250 paid
European Union 2025, 2 entries, €190,539 in total
Projects
- EMPOWERING RESEARCH TALENT: BUILDING R&I TALENT ECOSYSTEMS TO ADVANCE CAREERS IN HEALTH INNOVATIONHorizon Europe, 01-10-2025 to 30-09-2028, €190,539, BREATH
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 |
|---|---|---|
| -390,316 | ||
| -394,839 | ||
| 43,624 | ||
| 818,843 | ||
| -36.8% | ||
| 40.8% | ||
| 2.03 | ||
| 1.45 | ||
| -64.3% | ||
| -26.2% | ||
| -31.30 | ||
| 101 days | ||
| 84 days |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Social balance sheet
| Item | 31-12-2025 |
|---|---|
| Employees at the balance-sheet date | 17 |
| full-time | 10 |
| part-time | 7 |
| in full-time equivalents | 15.4 |
| 14 | |
| On a permanent contract | 17 |
| Joined | 22 |
| Left | 5 |
Source: social balance sheet in the 2025 annual accounts
Investments
fixed assets acquired| Item | 2025 |
|---|---|
| Tangible fixed assets | €28,583 |
| Intangible fixed assets | €15,041 |
| €108,240 |
Source: notes to the 2025 annual accounts (statement of fixed assets)
Insights on FBM
Debt's share of the balance-sheet total is 59.2%.
Board & ownership
Board
25 directors, no change since 2025Aphea.Bio NV
Director, permanent representative Isabel Julia René VERCAUTEREN
appointed by deed of 24-03-2025
term without a fixed end
Hippocreates BV
Director, permanent representative Dirk LOECKX
appointed by deed of 24-03-2025
term without a fixed end
Director, permanent representative Werner Hendrik Adolf VERBIEST
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 3 other companies
Director, permanent representative Christel Alphonsina Gabriella Godelieve VAN GEET
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 13 other companies
1 other company struck offDirector, permanent representative Kenneth Maria WILS
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 56 other companies
4 other companies bankrupt, 1 judicially dissolvedDirector, permanent representative Koen HASAERS
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 4 other companies
1 other company struck offSURGI-TEC NV
Director, permanent representative Karina Monique Angèle Anna SCHEERLINCK
appointed by deed of 24-03-2025
term without a fixed end
Director, permanent representative Guy Henri Joseph HANS
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 2 other companies
Director, permanent representative Jérôme Laurent Nicole VAN BIERVLIET
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 3 other companies
Ad Hoc Clinical
Director, permanent representative Nancy Cottigny
appointed by deed of 03-10-2025
4-year term from 2025
Director, permanent representative Lucas Decuypere
appointed by deed of 03-10-2025
4-year term from 2025
Benno Therapeutics
Director, permanent representative Erwin Blomsma
appointed by deed of 03-10-2025
4-year term from 2025
Show all 26 office holders
Flen Health
Director, permanent representative Philippe Sollie
appointed by deed of 03-10-2025
4-year term from 2025
Gynaia
Director, permanent representative Herman Verrelst
appointed by deed of 03-10-2025
4-year term from 2025
Director, permanent representative Dirk Reyn
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 1 other company
GALAPAGOS NV
Director, permanent representative Marieke Vermeersch
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 1 other company
Director, permanent representative Herman Verrelst
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 8 other companies
1 other company bankruptDirector, permanent representative Gil Beyen
appointed by deed of 24-03-2025
term without a fixed end
MoveUP NV
Director, permanent representative Ward Servaes
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 1 other company
QbD Group NV
Director, permanent representative Bart Van Acker
appointed by deed of 24-03-2025
term without a fixed end
also on the board of 1 other company
ViroVet NV
Director, permanent representative Erwin Blomsma
appointed by deed of 24-03-2025
term without a fixed end
Permanent representative
appointed by deed of 03-10-2025
also on the board of 3 other companies
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “ARTIKEL 18- VERTEGENWOORDIGING VAN DE VERENIGING De raad van bestuur vertegenwoordigt de vereniging, met inbegrip van de vertegenwoordiging…”deed of 10-12-2024
Permanent representatives 19
Christel Alphonsina Gabriella Godelieve VAN GEET
Permanent representative, for Katholieke Universiteit te Leuven
appointed by deed of 24-03-2025
Guy Henri Joseph HANS
Permanent representative, for Universitair Ziekenhuis Antwerpen
appointed by deed of 24-03-2025
Isabel Julia René VERCAUTEREN
Permanent representative, for Aphea.Bio
appointed by deed of 24-03-2025
Jérôme Laurent Nicole VAN BIERVLIET
Permanent representative, for VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
appointed by deed of 24-03-2025
Karina Monique Angèle Anna SCHEERLINCK
Permanent representative, for SURGI-TEC
appointed by deed of 24-03-2025
Kenneth Maria WILS
Permanent representative, for Participatiemaatschappij Vlaanderen
appointed by deed of 24-03-2025
Koen HASAERS
Permanent representative, for Studiecentrum voor Kernenergie - Centre d'Etude de l'Energie Nucléaire
appointed by deed of 24-03-2025
Permanent representative, for Janssen Pharmaceutica
appointed by deed of 24-03-2025
Mandates through the years
29 names, the dashed line is todayAphea.Bio
Director
Director
BIOQUBE VENTURES
Director
Director
GALAPAGOS
Director
Director
Heran Partners
Director
Director
Hippocreates
Director
Director
Janssen Pharmaceutica
Director
Director
Montis Biosciences
Director
Director
MoveUP
Director
Director
QbD Group
Director
Director
SURGI-TEC
Director
Director
ViroVet
Director
Director
KU LEUVEN
Director
Director
P.M.V. NV
Director
Director
SCK CEN
Director
Director
VIB VZW
Director
Director
Ad Hoc Clinical
Director
Director
Allegro
Director
Director
Benno Therapeutics
Director
Director
Flen Health
Director
Director
Gynaia
Director
Director
Tom Aelbrecht
Permanent representative
Permanent representative
Werner Verbiest
Permanent representative
Permanent representative
FlandersBIO
Director
Director
MEDVIA
Director
Director
BoardOther functionEarlierRest of the termmandate already running before its first mention
Mandates as a list
- Aphea.Bio
- Director, appointed by deed of 24-03-2025, still in office
- BIOQUBE VENTURES
- Director, appointed by deed of 24-03-2025, until 27-05-2025
- Director, appointed by deed of 24-03-2025, still in office
- GALAPAGOS
- Director, appointed by deed of 24-03-2025, until 27-05-2025
- Director, appointed by deed of 24-03-2025, still in office
- Heran Partners
- Director, appointed by deed of 24-03-2025, until 27-05-2025
- Director, appointed by deed of 24-03-2025, still in office
- Hippocreates
- Director, appointed by deed of 24-03-2025, still in office
- Janssen Pharmaceutica
- Director, appointed by deed of 24-03-2025, still in office
- Katholieke Universiteit te Leuven
- Director, appointed by deed of 24-03-2025, still in office
- Montis Biosciences
- Director, appointed by deed of 24-03-2025, until 27-05-2025
- Director, appointed by deed of 24-03-2025, still in office
- MoveUP
- Director, appointed by deed of 24-03-2025, until 27-05-2025
- Director, appointed by deed of 24-03-2025, still in office
- Participatiemaatschappij Vlaanderen
- Director, appointed by deed of 24-03-2025, still in office
- QbD Group
- Director, appointed by deed of 24-03-2025, until 27-05-2025
- Director, appointed by deed of 24-03-2025, still in office
- Studiecentrum voor Kernenergie - Centre d'Etude de l'Energie Nucléaire
- Director, appointed by deed of 24-03-2025, still in office
- SURGI-TEC
- Director, appointed by deed of 24-03-2025, still in office
- Universitair Ziekenhuis Antwerpen
- Director, appointed by deed of 24-03-2025, still in office
- ViroVet
- Director, appointed by deed of 24-03-2025, until 27-05-2025
- Director, appointed by deed of 24-03-2025, still in office
- VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
- Director, appointed by deed of 24-03-2025, still in office
- KU LEUVEN
- Director, appointed by deed of 24-03-2025, still in office
- P.M.V. NV
- Director, appointed by deed of 24-03-2025, still in office
- SCK CEN
- Director, appointed by deed of 24-03-2025, still in office
- VIB VZW
- Director, appointed by deed of 24-03-2025, still in office
- Ad Hoc Clinical
- Director, appointed by deed of 03-10-2025, still in office
- Allegro
- Director, appointed by deed of 03-10-2025, still in office
- Benno Therapeutics
- Director, appointed by deed of 03-10-2025, still in office
- Flen Health
- Director, appointed by deed of 03-10-2025, still in office
- Gynaia
- Director, appointed by deed of 03-10-2025, still in office
- Tom Aelbrecht
- Permanent representative, appointed by deed of 03-10-2025, still in office
- Werner Verbiest
- Permanent representative, until 23-05-2025
- FlandersBIO
- Director, appointed by deed of 10-12-2024, until 24-03-2025
- MEDVIA
- Director, appointed by deed of 10-12-2024, until 24-03-2025
Control
Articles of association
deed of 10-12-2024 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- 2 directors“Vergoeding indien raad van bestuur bepaalt,bedrag en modaliteiten door raad,per werkingsjaar goed te keuren op algemene vergadering…”“Vergoeding bestuurders, kosteloos tenzij algemene vergadering anders bepaalt”“Tot dag waarop aantal werkelijke leden groter is dan twee”
Founders
At incorporation
deed of 10-12-2024 ↗
- FLANDERS.BIO VZW (BE 0863.763.620) founder
- MEDVIA VZW (BE 0772.406.446) founder
The directors' other companies
4 current directors with another company that went bankrupt, was dissolved or struck off4 other companies of this director went bankrupt (2023, 2025, 2026) and 1 was judicially dissolved (2025).
- QOLLABI bankruptcy on 07-05-2026Official Gazetteappointed in 2022, still in office
- REIN4CED bankruptcy on 29-12-2025Official Gazetteappointed in 2022, still in office
- OXYPOINT bankruptcy on 11-12-2025Official Gazettemandate 2020 to 2022
- OTRA SOLUTIONS judicial dissolution on 20-11-2025Official Gazetteappointed in 2021, still in office
- VILOC bankruptcy on 26-01-2023Official Gazettemandate until 2022
1 other company of this director went bankrupt (2025).
- FOx Biosystems bankruptcy on 23-01-2025Official Gazetteappointed in 2020, still in office
1 other company of this director was struck off by the FPS Economy (2024).
- BELGIAN ENERGY RESEARCH ALLIANCE struck off on 02-09-2024Official Gazetteappointed in 2024, still in office
1 other company of this director was struck off by the FPS Economy (2024).
- BELGIAN ENERGY RESEARCH ALLIANCE struck off on 02-09-2024Official Gazetteappointed in 2024, still in office
Source: Belgian Official Gazette (bankruptcies, judicial dissolutions, board mandates), FPS Economy (strike-offs) and the KBO register. A bankruptcy, dissolution or strike-off says nothing about the director's part in it.
Network & group
No group
FBM has no parent and no holdings in its annual accounts.
Earlier ties
| Transnubel via Studiecentrum voor Kernenergie - Centre d'Etude de l'Energie Nucléaire, no longer at Transnubel · Director · deed of 15-10-2021 founded in 1969 · negative equity (2025) · group ENGIE |
248 FTE (2025) |
| ASPECT ANALYTICS via Heran Partners, no longer at ASPECT ANALYTICS · Director · deed of 19-09-2025 founded in 2018 |
5.7 FTE (2025) |
| INTERGEMEENTELIJKE VERENIGING VOOR BEHEER VAN AFVALSTOFFEN VLAAMSE ARDENNEN via Tom Aelbrecht, no longer at INTERGEMEENTELIJKE VERENIGING VOOR BEHEER VAN AFVALSTOFFEN VLAAMSE ARDENNEN · Director · deed of 03-01-2020 founded in 1986 |
4 FTE (2025) |
| Catalisti via Janssen Pharmaceutica (no longer at Catalisti) and Katholieke Universiteit te Leuven (no longer at Catalisti) · Director · deeds of 02-12-2021 and 23-12-2011 founded in 2011 |
9.2 FTE (2025) |
| DE WOLKAMMERIJ via Janssen Pharmaceutica, no longer at DE WOLKAMMERIJ · Director · deed of 18-10-2022 founded in 2001 |
total assets €1.4m (2025) |
| PALLIATIEF NETWERK ARRONDISSEMENT LEUVEN via Katholieke Universiteit te Leuven, no longer at PALLIATIEF NETWERK ARRONDISSEMENT LEUVEN · Director · deed of 14-11-2023 founded in 1995 |
13 FTE (2025) |
Show 1 more earlier tie
| PERSOMED via QbD Group, no longer at PERSOMED · Director · deed of 11-04-2023 No longer active |
total assets €16,271 (2023) |
Acquisitions and mergers
2 transactionsTook over:FLANDERS.BIO
Took over:MEDVIA
Connections & network
32 connected companiesThis company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
FOx Biosystems
via Heran Partners · Director · deed of 06-07-2020
Open bankruptcy · founded in 2016 · 14 FTE (2023)
→
icometrix
via Heran Partners · Class B director · deed of 10-08-2020
Founded in 2011 · 25 FTE (2025) · negative equity
→
UgenTec
via Heran Partners · Class B director · deed of 30-11-2020
Founded in 2014 · 2.8 FTE (2025) · negative equity
→
ONTOFORCE
via Heran Partners · Director (not named in the articles) · deed of 03-08-2020
Founded in 2011 · 23 FTE (2025) · negative equity
→
Show 28 more companies with a shared director
Lynxcare Clinical Informatics
via Heran Partners · Director · deed of 19-03-2026
Founded in 2015 · 14 FTE (2025) · negative equity
→
J.C. GENERAL SERVICES
via Tom Aelbrecht · Director · deed of 30-12-2024
Founded in 2000 · total assets €36.78bn (2025) · group Johnson & Johnson
→
Janssen Pharmaceutica
via Tom Aelbrecht · Managing director · deed of 26-06-2026
Founded in 1934 · 5,325 FTE (2025) · group Johnson & Johnson
→
BIOQUBE FACTORY FUND I
via BIOQUBE VENTURES · Manager · deed of 04-06-2020
Founded in 2020 · total assets €68.3m (2025)
→
Heran HealthTech Fund I
via Heran Partners · Manager · deed of 29-05-2020
Founded in 2020 · total assets €28.8m (2026)
→
Biotalys
via VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY · Director · deed of 17-01-2013
Founded in 2013 · 58 FTE (2025)
→
Magics Technologies
via Studiecentrum voor Kernenergie - Centre d'Etude de l'Energie Nucléaire · Director · deed of 03-08-2023
Founded in 2015 · 39 FTE (2025)
→
Voka - Kamer van koophandel Mechelen-Kempen
via Tom Aelbrecht · Director · deed of 08-06-2026
Founded in 1980 · 47 FTE (2025)
→
VIL
via Katholieke Universiteit te Leuven · Director · deed of 24-07-2025
Founded in 2003 · 19 FTE (2025)
→
GS1 Belgium & Luxembourg
via Janssen Pharmaceutica and Katholieke Universiteit te Leuven · Director · deeds of 22-12-2025 and 26-03-2024
Founded in 1978 · 47 FTE (2025)
→
→
→
ORSI Academy
via Katholieke Universiteit te Leuven · Director · deed of 31-07-2026
Founded in 2010 · turnover €237,028 (2025)
→
nuclivision
via Heran Partners · Director · deed of 09-05-2025
Founded in 2022 · total assets €2.0m (2025)
→
Palliatieve Hulpverlening Antwerpen
via Universitair Ziekenhuis Antwerpen · Director · deed of 18-01-2024
Founded in 1992 · 17 FTE (2025)
→
Kwaliteitscentrum voor Diagnostiek
via Katholieke Universiteit te Leuven · Director · deed of 17-12-2024
Founded in 2014 · 10 FTE (2025)
→
Groovy.Bio
via BIOQUBE VENTURES · Director · deed of 10-11-2021
Founded in 2021 · 0.2 FTE (2025) · group BIOQUBE FACTORY FUND I
→
Vlaamse Erfgoedbibliotheken
via Katholieke Universiteit te Leuven · Day-to-day manager · deed of 02-01-2026
Founded in 2008 · 7.4 FTE (2025)
→
Forum Nucléaire Belge-Belgisch Nucleair Forum
via Studiecentrum voor Kernenergie - Centre d'Etude de l'Energie Nucléaire · Director · deed of 11-12-2023
Founded in 1957 · 1 FTE (2025)
→
Archiefpunt
via Katholieke Universiteit te Leuven · Director · deed of 20-07-2021
Founded in 2008 · 6.2 FTE (2025)
→
BELGIAN ENERGY RESEARCH ALLIANCE
via Studiecentrum voor Kernenergie - Centre d'Etude de l'Energie Nucléaire and Katholieke Universiteit te Leuven · Director · deed of 19-08-2024
Founded in 2012
→
EU-LIFE
via VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY · Director · deed of 11-06-2026
Founded in 2026
→
Federated Healthcare Innovation Network
via Universitair Ziekenhuis Antwerpen and Katholieke Universiteit te Leuven · Director · deeds of 28-11-2025 and 10-03-2025
Founded in 2024
→
HIKempen Stichting
via Katholieke Universiteit te Leuven · Director · deed of 15-01-2024
Founded in 2013
→
Immunity for Health
via Katholieke Universiteit te Leuven, ViroVet (no longer at Immunity for Health) and FlandersBIO (at FBM until 2025) · Director · deeds of 10-07-2025 and 12-07-2021
Founded in 2016
→
Stichting Administratiekantoor Hippocreates
via Hippocreates · Director (not named in the articles) · deed of 14-09-2023
Founded in 2023
→
Vlaamse Lucht - Ruimtevaart Initiatieven
via Katholieke Universiteit te Leuven · Director · deed of 25-06-2024
Founded in 1993
→
→
Timeline
Timeline
9 events since 2024Board
Capital
Filings
Establishments
Other
202420252026
2026
Powers of attorney: Frederik Van Remoortel, Ward Overlaet and Anass ArbagePermanent representatives: Kenneth Wills and Bart De Taeye · Board meeting of 23-04-20266 points ▸
- Board meeting, 23-04-2026
- Permanent representative, Kenneth Wills
- Permanent representative, Bart De Taeye
- Power of attorney, Frederik Van Remoortel
- Power of attorney, Ward Overlaet
- Power of attorney, Anass Arbage
Annual accounts 2025 filed PDFabbreviated format · 65 days before the deadline
2025
6 directors appointed, 8 resignationsResignations: Galapagos, Virovet, MoveUp, Montis Biosciences, QbD 'Group, Heran Partners and 2 others · Permanent representatives: Marieke Vermeersch, Erwin Blomsma, Ward Servaes, Gil Beyen, Bart Van Acker, Herman Verrelst and 4 others · Appointments: Allegro, Flen Health, Benno Therapeutics, Gynaia, Ad Hoc Clinical and Tom Aelbrecht (permanent representative) · General meeting of 27-05-202526 points ▸
- General meeting, 27-05-2025
- Director resignation, Galapagos
- Permanent representative, Marieke Vermeersch
- Director resignation, Virovet
- Permanent representative, Erwin Blomsma, mentioned twice in the deed
- Director resignation, MoveUp
- Permanent representative, Ward Servaes
- Director resignation, Montis Biosciences
- Permanent representative, Gil Beyen
- Director resignation, QbD 'Group
- Permanent representative, Bart Van Acker
- Director resignation, Heran Partners
- Permanent representative, Herman Verrelst, mentioned twice in the deed
- Director resignation, BioQube Ventures
- Permanent representative, Dirk Reyn
- Director appointment, Allegro
- Permanent representative, Lucas Decuypere
- Director appointment, Flen Health
- Permanent representative, Philippe Sollie
- Director appointment, Benno Therapeutics
- Director appointment, Gynaia
- Director appointment, Ad Hoc Clinical
- Permanent representative, Nancy Cottigny
- Board meeting, 23-05-2025
- Director resignation, Werner Verbiest (permanent representative)
- Director appointment, Tom Aelbrecht (permanent representative)
Merger: FBM takes over FLANDERS.BIOAppointments: MONTIS BIOSCIENCES BV, APHEA.BIO NV, VIROVET NV, GALAPAGOS NV, VIB VZW, P.M.V. NV and 10 others · Permanent representatives: Gil Hendrik August BEYEN, Isabel Julia René VERCAUTEREN, Erwin BLOMSMA, Marieke Francine VERMEERSCH, Jérôme Laurent Nicole VAN BIERVLIET, Kenneth Maria WILS and 10 others · Resignations: FLANDERS.BIO (director) and MEDVIA (director) · General meeting of 18-02-202537 points ▸
- General meeting, 18-02-2025
- Director appointment, MONTIS BIOSCIENCES BV
- Permanent representative, Gil Hendrik August BEYEN
- Director appointment, APHEA.BIO NV
- Permanent representative, Isabel Julia René VERCAUTEREN
- Director appointment, VIROVET NV
- Permanent representative, Erwin BLOMSMA
- Director appointment, GALAPAGOS NV
- Permanent representative, Marieke Francine VERMEERSCH
- Director appointment, VIB VZW
- Permanent representative, Jérôme Laurent Nicole VAN BIERVLIET
- Director appointment, P.M.V. NV
- Permanent representative, Kenneth Maria WILS
- Director appointment, QBD GROUP NV
- Permanent representative, Bart Jeanne Freddy VAN ACKER
- Director appointment, BIOQUBE VENTURES NV
- Permanent representative, Dirk Maria Jozef REYN
- Director appointment, HIPPOCREATES BV
- Permanent representative, Dirk LOECKX
- Director appointment, SURGI-TEC NV
- Permanent representative, Karina Monique Angèle Anna SCHEERLINCK
- Director appointment, JANSSEN PHARMACEUTICA NV
- Permanent representative, Werner Hendrik Adolf VERBIEST
- Director appointment, KU LEUVEN
- Permanent representative, Christel Alphonsina Gabriella Godelieve VAN GEET
- Director appointment, UNIVERSITAIR ZIEKENHUIS ANTWERPEN (UZA)
- Permanent representative, Guy Henri Joseph HANS
- Director appointment, MOVEUP NV
- Permanent representative, Ward Marie Louis SERVAES
- Director appointment, SCK CEN
- Permanent representative, Koen HASAERS
- Director appointment, Heran Partners BV
- Permanent representative, Herman Karel Gabriel VERRELST
- Director resignation, FLANDERS.BIO
- Director resignation, MEDVIA
- Net-asset statement, 611390.23, 30-11-2024
- Accounting effect, 01-01-2025
- The deed holds 10 more points.
Registered in the Peppol Directory Reachable for e-invoices through 0208:1016786167
Amendment of the articlesGeneral meeting of 06-01-20252 points ▸
- General meeting, 06-01-2025
- Amendment of the articles, article 12
Powers of attorney: Ann Van Gysel and Marc OstBoard meeting of 22-01-20253 points ▸
- Board meeting, 22-01-2025
- Power of attorney, Ann Van Gysel
- Power of attorney, Marc Ost
First establishment Stapelplein 70, Ghent
2024
IncorporationFounders: FLANDERS.BIO VZW and MEDVIA VZW · Appointments: FLANDERS.BIO VZW (director) and MEDVIA VZW (director) · Permanent representatives: Dirk Reyn and Herman Verrelst · published on 10-12-20247 points ▸
- Founder, FLANDERS.BIO VZW
- Founder, MEDVIA VZW
- Registered office clause, Sint-Michielsstraat 18, 9000 Gent
- Director appointment, FLANDERS.BIO VZW
- Permanent representative, Dirk Reyn
- Director appointment, MEDVIA VZW
- Permanent representative, Herman Verrelst
- The deed holds 1 more point.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
FBM was incorporated on 29 November 2024 as a non-profit association by FLANDERS.BIO VZW and MEDVIA VZW.12 In 2025 the company absorbed FLANDERS.BIO and MEDVIA by merger.34 The board currently has 25 members.5
Company details
Identity
- Enterprise number
- 1016.786.167
- VAT number
- BE 1016.786.167
- Peppol ID
- 0208:1016786167
- Other Peppol ID
- 9925:BE1016786167
- Legal form
- Non-profit association
- Status
- Active, normal situation
- Founded
- 29-11-2024
- Financial year
- ends on 31 December
- Peppol
- Reachable since 05-03-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- FBM in Dutch
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 10-12-2024 (in Dutch)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Vlaams Gewest”deed of 10-12-2024 (in Dutch)
Activities
NACEBEL 2025VAT activities
82990
Other business support services main activity
Social security (RSZ) activities
94110
Activities of business and employers' organisations main activity
Joint committees annual accounts 2025
JC 335
Services and support for business and the self-employed
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Bedrijven en onderzoeksinstellingen met actieve R&D- en/of Support - en/of productieactiviteiten in Vlaanderen in de Biotech en HealthTech…”deed of 10-12-2024 (in Dutch)
Text of the purpose
“Bedrijven en onderzoeksinstellingen met actieve R&D- en/of Support - en/of productieactiviteiten in Vlaanderen in de Biotech en HealthTech domeinen,met inbegrip van Biopharma,Animal Health,Agrotech,Medtech,Digital Health e.a.,te verenigen en te ondersteunen.”
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Sint-Michielsstraat 18 registered office 9000 Ghent | ||
| Stapelplein 70 9000 Ghent 94110 Activities of business and employers' organisations | 18-02-2025 | 2.370.455.316 |
Buildings and parcels at the addresses
- Ground area
- 4,572 m²
- Buildings
- 2,313 m²
- Volume, LiDAR
- 37,670 m³
- Tallest building
- 22.6 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 44021A2756/02F002 | 4,237 m² | 1 · 1,979 m² | 21.2 m · 5 |
| 44815F1325/00D000 | 334 m² | 1 · 334 m² | 22.6 m · 5 |
1 of these parcels carries protected heritage. Expect extra rules on renovation or sale.